Pharmacologic characterization of the novel, orally available endothelin-A - Selective antagonist SB 247083

Journal of Cardiovascular Pharmacology

Volumn 31, Issue SUPPL. 1, 1998, Pages

  Douglas, Stephen A ^a   Nambi, Ponnal ^a   Gellai, Miklos ^a   Luengo, Juan I ^a   Xiang, Jia Ning ^a   Brooks, David P ^a   Ruffolo Jr , Robert R ^a   Elliott, John D ^a   Ohlstein, Eliot H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antagonist; Endothelin; ETA selectivity; Hemodynamics; SB 247083; Vasoconstriction

Indexed keywords

BENZOFURAN DERIVATIVE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; PROPIONIC ACID DERIVATIVE; SARAFOTOXINS S6; SB 247083; VASOCONSTRICTOR AGENT; VIPER VENOM;

ANIMAL; ARTICLE; BLOOD PRESSURE; CHO CELL; DRUG ANTAGONISM; DRUG EFFECT; HAMSTER; HUMAN; METABOLISM; MUSCLE CONTRACTION; RABBIT; RAT; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; BENZOFURANS; BLOOD PRESSURE; CHO CELLS; CRICETINAE; ENDOTHELIN-1; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PROPIONIC ACIDS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; VASOCONSTRICTOR AGENTS; VIPER VENOMS;

EID: 0031630239     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800001-00077     Document Type: Article

References (15)

1. Ohlstein EH et al. Endothelin receptors: from the gene to the human. Boca Raton, FL: CRC Press, 1995:109-85.
2. Douglas SA, Meek TD, Ohlstein EH. Novel receptor antagonists welcome a new era in endothelin biology. Trends Pharmacol Sci 1994;15:313-6.
3. Warner TD et al. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol 1993;22(suppl 8):S117-20.
4. Douglas SA et al. Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in rabbit lateral saphenous vein. Br J Pharmacol 1995;114:1529-40.
5. Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 1994;46:137-42.
6. Ohlstein EH et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994;91:8052-6.
7. Ohlstein EH et al. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996;276:609-15.
8. Clozel M et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
9. B receptor antagonist Ro 46-8443. FEBS Lett 1996;383:42-5.
10. Brandli P et al. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 1996;64:315-22.
11. A receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 1995;115:191-7.
12. B receptors in rats. Biochem Biophys Res Commun 1994;199: 1461-5.
13. Douglas SA. Clinical development of endothelin receptor antagonists. Trends Pharmacol Sci 1997;18:408-12.
14. Nambi P et al. Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors. J Pharmacol Exp Ther 1994;271:755-61.
15. Willette RN. Plasma- and cerebrospinal fluid immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors. J Cardiovasc Pharmacol 1998;31(suppl 1):S149-57 (this issue).